|
|
Reference
|
|
  
|
Abrahami, D., McDonald, E.G., Schnitzer, M.E., Barkun, A.N., Suissa, S., Azoulay, L. (2022) Proton pump inhibitors and risk of gastric cancer: Population-based cohort study. Gut, 71(1): 16-24
|
|
|
Agewall, S., Cattaneo, M., Collet, J.P., Andreotti, F., Lip, G.Y.H., Verheugt, F.W.A., Huber, K., Grove, E.L., Morais, J., Husted, S., Wassmann, S., Rosano, G., Atar, D., Pathak, A., Kjeldsen, K., Storey, R.F. (2013) Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. European Heart Journal, 34(23): 1708-1713
|
|
|
Ahn, J.S., Eom, C.S., Jeon, C.Y., Min, P.S. (2013) Acid suppressive drugs and gastric cancer: A meta-analysis of observational studies. World Journal of Gastroenterology, 19(16):2560-8
|
|
|
Almario, C.V., Chey, W.D., Spiegel, B. (2020) Increased risk of COVID-19 among users of Proton Pump Inhibitors. Am J Gastroenterol, 115(10): 1707-1715
|
|
|
Antoniou, T., Macdonald, E.M., Hollands, S., Gomes, T., Mamdani, M.M., Garg, A.X., Paterson, J.M., Juurlink, D.N. (2015) Proton pump inhibitors and the risk of acute kidney injury in older patients: A population-based cohort study. CMAJ Open, 3(2): E166-E171
|
|
|
Arora, P., Gupta, A., Golzy, M., Patel, N., Carter, R.L., Jalal, K., Lohr, J.W. (2016) Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrology, 17(1): 116-116
|
|
|
Attwood, S.E., Ell, C., Galmiche, J.P., Fiocca, R., Hatlebakk, J.G., Hasselgren, B., Långström, G., Jahreskog, M., Eklund, S., Lind, T., Lundell, L. (2015) Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: Data from the SOPRAN and LOTUS studies. Alimentary Pharmacology & Therapeutics, 41(11): 1162-1174
|
|
2
|
Bavishi, C., Dupont, H.L. (2011) Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection. Alimentary Pharmacology & Therapeutics, 34(11-12), 1269-1281
|
|
|
Bjorkman, D.J., Estborn, L., Joelson, S. (2015) Esomeprazole and respiratory tract infections. Aliment Pharmacol Ther, https://www.jwatch.org/na38529/2015/07/24/eso meprazole-and-respiratory-tract-infections (preuzeto 01.08.2022)
|
|
|
Blank, M.L., Parkin, L., Paul, C., Herbison, P. (2014) A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney International, 86(4): 837-844
|
|
|
Brophy, S., Jones, K.H., Rahman, M.A., Zhou, S.M., John, A., Atkinson, M.D., Francis, N., Lyons, R.A., Dunstan, F. (2013) Incidence of campylobacter and salmonella infections following first prescription for PPI: A cohort study using routine data. American Journal of Gastroenterology, 108(7): 1094-1100
|
|
|
Brunner, G., Athmann, C., Schneider, A. (2012) Long-term, open-label trial: Safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Alimentary Pharmacology & Therapeutics, 36(1): 37-47
|
|
|
Cardoso, R.N., Benjo, A.M., Dinicolantonio, J.J., Garcia, D.C., Macedo, F.Y.B., El-Hayek, G., Nadkarni, G.N., Gili, S., Iannaccone, M., Konstantinidis, I., Reilly, J.P. (2015) Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: An updated meta-analysis. Open Heart, 2(1): e000248-e000248
|
|
|
Cheng, Z., Liu, Y., Ma, M., Sun, S., Ma, Z., Wang, Y., Yu, L., Qian, X., Sun, L., Zhang, X., Liu, Y., Wang, Y. (2022) Lansoprazole-induced osteoporosis via the IP3Rand SOCE-mediated calcium signaling pathways. Molecular Medicine, 28(1): 21-21
|
|
|
Clooney, A.G., Bernstein, C.N., Leslie, W.D., Vagianos, K., Sargent, M., Laserna-Mendieta, E.J., Claesson, M.J., Targownik, L.E. (2016) A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Alimentary Pharmacology & Therapeutics, 43(9): 974-984
|
|
|
Cooksey, R., Kennedy, J., Dennis, M.S., Escott-Price, V., Lyons, R.A., Seaborne, M., Brophy, S. (2020) Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK. PLoS One, 15(9): e0237676-e0237676
|
|
|
Estborn, L., Joelson, S. (2015) Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: A retrospective analysis of patient-level data in placebo-controlled studies. Alimentary Pharmacology & Therapeutics, 42(5): 607-613
|
|
|
Fatima, K., Almas, T., Lakhani, S., Jahangir, A., Siddiqui, A.A., et al. (2022) The use of proton pump inhibitors and COVID-19: A systematic review and meta-analysis. Trop Med Infect Dis, 7(3): 37-37; PMCID: PMC8950138
|
|
1
|
Filion, K.B., Chateau, D., Targownik, L.E., Gershon, A., Durand, M.A., Tamim, H., Teare, G.F., Ravani, P.F., Ernst, P., Dormuth, C.R. (2014) Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: Replicated cohort studies with meta-analysis. Gut, 63(4): 552-558
|
|
|
Funck-Brentano, C., Szymezak, J., Steichen, O., Ducint, D., Molimard, M., et al. (2013) Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Arch Cardiovasc Dis, 106(12):661-71; Epub 2013 Nov 15
|
|
|
Goldstein, F.C., Steenland, K., Zhao, L., Wharton, W., Levey, A.I., Hajjar, I. (2017) Proton pump inhibitors and risk of mild cognitive impairment and dementia. J Am Geriatr Soc, 65(9): 1969-74
|
|
|
Gomm, W., von Holt, K., Thomé, F., Broich, K., Maier, W., Fink, A., et al. (2016) Association of proton pump inhibitors with risk of dementia: A pharmacoepidemiological claims data analysis. JAMA Neurol, 73(4): 410-416
|
|
|
Gray, S.L., Lacroix, A.Z., Larson, J., Robbins, J., Cauley, J.A., Manson, J.E., et al. (2010) Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: Results from the Women's Health Initiative. Archives of Internal Medicine, 170(9): 765-765
|
|
|
Haenisch, B., von Holt, K., Wiese, B., Prokein, J., Lange, C., Ernst, A., Brettschneider, C., König, H., Werle, J., Weyerer, S., Luppa, M., Riedel-Heller, S.G., Fuchs, A., Pentzek, M., Weeg, D. (2015) Risk of dementia in elderly patients with the use of proton pump inhibitors. European Archives of Psychiatry and Clinical Neuroscience, 265(5): 419-428
|
|
|
Hanžel, J., Golob, S., Štabuc, B. (2020) Neželeni učinki zaviralcev protonske črpalke in tveganje za potek bolezni COVID-19. Gastroenterolog, 2: 25-33
|
|
2
|
Janarthanan, S., Ditah, I., Adler, D.G., Ehrinpreis, M.N. (2012) Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: A meta-analysis. Am J Gastroenterol, 107(7): 1001-1010
|
|
|
Klatte, D.C.F., Gasparini, A., Xu, H., de Deco, P., Trevisan, M., Johansson, A.L.V., Wettermark, B., Ärnlöv, J., Janmaat, C.J., Lindholm, B., Dekker, F.W., Coresh, J., Grams, M.E., Carrero, J.J. (2017) Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology, 153(3): 702-710
|
|
|
Kow, C.S., Hasan, S.S. (2021) Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: A meta-analysis. Journal of Internal Medicine, 289(1): 125-128
|
|
2
|
Kwok, C.S., Arthur, A.K., Anibueze, C.I., Singh, S., Cavallazzi, R., Loke, Y.K. (2012) Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: Meta-analysis. Am J Gastroenterol, 107(7): 1011-9
|
|
|
Lam, J.R., Schneider, J.L., Zhao, W., Corley, D.A. (2013) Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA, 310(22):2435-42
|
|
|
Lam, J.R., Schneider, J.L., Quesenberry, C.P., Corley, D.A. (2017) Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology, 152(4):821-9.e1
|
|
|
Lambert, A.A., Lam, J.O., Paik, J.J., Ugarte-Gil, C., Drummond, M., Crowell, T.A. (2015) Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: A systematic review and meta-analysis. PLoS One, 10(6):e0128004
|
|
|
Lazarus, B., Chen, Y., Wilson, F.P., Sang, Y., Chang, A.R., Coresh, J., Grams, M.E. (2016) Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Internal Medicine, 176(2):238-46
|
|
|
Lee, S.W., Ha, E.K., Yeniova, A.Ö., Moon, S.Y., Kim, S.Y., Koh, H.Y., Yang, J.M., Jeong, S.J., Moon, S.J., Cho, J.Y., Yoo, I.K., Yon, D.K. (2021) Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: A nationwide cohort study with propensity score matching. Gut, 70(1): 76-84
|
|
|
Leonard, J., Marshall, J.K., Moayyedi, P. (2007) Systematic review of the risk of enteric infection in patients taking acid suppression. American Journal of Gastroenterology, 102(9): 2047-2056
|
|
|
Li, J., Cao, J., Cai, P., Shi, B., Cao, J., Zhang, Y., Wang, J. (2020) Risk factors of secondary infections in severe and critical patients hospitalized with COVID-19: A case-control study. Research Square, Preprint
|
|
|
Lin, W.L., Muo, C.S., Lin, W.L., Hsieh, Y.W., Kao, C.H. (2019) Association of increased risk of pneumonia and using proton pump inhibitors in patients with type II diabetes mellitus. Dose-Response, 17(2):1559325819843383
|
|
|
Lochhead, P., Hagan, K., Joshi, A.D., Khalili, H., Nguyen, L.H., Grodstein, F., et al. (2017) Association between proton pump inhibitor use and cognitive function in women. Gastroenterology, 153(4):971-9.e4
|
|
|
Luxenburger, H., Sturm, L., Biever, P., Rieg, S., Duerschmied, D., Schultheiss, M., Neumann-Haefelin, C., Thimme, R., Bettinger, D. (2021) Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: Coincidence or underestimated risk factor?. Journal of Internal Medicine, 289(1): 121-124
|
|
|
Mckeigue, P.M., Kennedy, S., Weir, A., et al. (2021) Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study. BMC Med, 19(1): 51-51
|
|
|
Moledina, D.G., Perazella, M.A. (2016) PPIs and kidney disease: From AIN to CKD. Journal of Nephrology, 29(5): 611-616
|
|
|
Ngamruengphong, S., Leontiadis, G.I., Radhi, S., Dentino, A., Nugent, K. (2011) Proton pump inhibitors and risk of fracture: A systematic review and meta-analysis of observational studies. American Journal of Gastroenterology, 106(7): 1209-1218
|
|
|
Ramachandran, P., Perisetti, A., Gajendran, M., Jean-Louis, F., Dwivedi, A.K., Goyal, H. (2020) Prehospitalization Proton Pump Inhibitor (PPI) use and Clinical Outcomes in COVID-19. medRxiv, Preprint; 2020.07.12.20151084
|
|
1
|
Rašić, J., Rašić, D., Janićijević-Hudomal, S., Nestorović, V. (2013) Inhibitori protonske pumpe - primena i bezbednost. Biomedicinska istraživanja, 4: 48-56; Pregled literature UDK: 616.333-008.8:615.03
|
|
|
Ray, A., Sharma, S., Sadasivam, B. (2020) The potential therapeutic role of proton pump inhibitors in COVID-19: Hypotheses based on existing evidences. Drug Res (Stuttg), 70(10):484-488; Epub 2020 Sep 2; PMCID: PMC7672704
|
|
|
Rosenberg, V., Tzadok, R., Chodick, G., Kariv, R. (2021) Proton pump inhibitors long term use-trends and patterns 15 y f organization. Pharmacoepidemiol Drug Saf, 30(11): 1576-1587
|
|
|
Sarzynski, E., Puttarajappa, C., Xie, Y., Grover, M., Laird-Fick, H. (2011) Association between proton pump inhibitor use and anemia: A retrospective cohort study. Digestive Diseases and Sciences, 56(8): 2349-2353
|
|
|
Savarino, V., Dulbecco, P., de Bortoli, N., Ottonello, A., Savarino, E. (2017) The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. European Journal of Internal Medicine, 37: 19-24
|
|
|
Schneider, J.L., Kolitsopoulos, F., Corley, D.A. (2016) Risk of gastric cancer, gastrointestinal cancers and other cancers: A comparison of treatment with pantoprazole and other proton pump inhibitors. Alimentary Pharmacology & Therapeutics, 43(1): 73-82
|
|
|
Sharara, A.I., Chalhoub, J.M., Hammoud, N., Harb, A.H., Sarkis, F.S., Hamadeh, G. (2016) Low prevalence of hypomagnesemia in long-term recipients of proton pump inhibitors in a managed care cohort. Clinical Gastroenterology and Hepatology, 14(2): 317-321
|
|
|
Tai, S., Chien, C., Wu, D., Lin, K., Ho, B., Chang, Y., Chang, Y. (2017) Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan. PLoS One, 12(2): e0171006-e0171006
|
|
|
Taipale, H., Tolppanen, A., Tiihonen, M., Tanskanen, A., Tiihonen, J., Hartikainen, S. (2017) No association between proton pump inhibitor use and risk of Alzheimer's disease. American Journal of Gastroenterology, 112(12): 1802-1808
|
|
|
Targownik, L.E., Lix, L.M., Leung, S., Leslie, W.D. (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology, 138(3): 896-904
|
|
|
Taştemur, Ş., Ataseven, H. (2020) Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?. Med Hypotheses, 143:110018; Epub 2020 Jun 20
|
|
1
|
Tran-Duy, A., Spaetgens, B., Hoes, A.W., de Wit, N.J., Stehouwer, C.D.A. (2016) Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 14(12):1706-19
|
|
|
Vaezi, M.F., Yang, Y., Howden, C.W. (2017) Complications of proton pump inhibitor therapy. Gastroenterology, 153(1): 35-48
|
|
|
Xie, Y., Bowe, B., Li, T., Xian, H., Balasubramanian, S., Al-Aly, Z. (2016) Proton pump inhibitors and risk of incident CKD and progression to ESRD. Journal of the American Society of Nephrology, 27(10): 3153-3163
|
|
|
Zhou, B., Huang, Y., Li, H., Sun, W., Liu, J. (2016) Proton-pump inhibitors and risk of fractures: An update meta-analysis. Osteoporosis International, 27(1): 339-347
|
|
|
|
|